白血病抑制因子增强效应揭示TYK2信号在血管钙化中的关键作用
该研究探讨白血病抑制因子(LIF)在慢性肾脏病(CKD)血管平滑肌细胞(VSMC)钙化中的作用。磷酸盐暴露增加VSMC中LIF表达,LIF补充加重钙化,而沉默内源性LIF或LIF受体(LIFR)则减轻磷酸盐的促钙化效应。可溶性LIFR拮抗LIF并减少VSMC钙化。机制上,LIF诱导TYK2和STAT3磷酸化;TYK2抑制剂deucravacitinib不仅减弱LIF效应,还干扰磷酸盐诱导的促钙化作用。TYK2过表达加重VSMC钙化;小鼠主动脉环外植体钙化经TYK2药理学抑制和遗传缺陷改善;胆钙化醇诱导的小鼠血管钙化经Tyk2抑制和Tyk2缺陷改善;Abcc6/Tyk2缺陷小鼠在腺嘌呤/高磷诱导CKD后钙化减轻。结论提示LIF参与CKD相关血管钙化,TYK2信号在其中发挥核心促钙化作用,可能成为未来减轻CKD血管钙化负担的靶点。
要点
- LIF补充加重VSMC钙化,沉默LIF或LIFR减轻磷酸盐促钙化效应
- TYK2抑制剂deucravacitinib减弱LIF效应并干扰磷酸盐促钙化
- TYK2抑制或缺陷改善小鼠主动脉环及体内血管钙化
核心结论
- LIF参与CKD相关血管钙化,TYK2信号在其中发挥核心促钙化作用,可能成为未来治疗靶点。
研究设计与样本
- 研究在VSMC、小鼠主动脉环外植体及多种小鼠模型(胆钙化醇诱导、Abcc6/Tyk2缺陷伴腺嘌呤/高磷诱导CKD)中探讨LIF和TYK2的作用。
主要发现
- 磷酸盐暴露增加VSMC中LIF表达;LIF补充加重钙化,而沉默内源性LIF或LIFR减轻磷酸盐促钙化效应。
- 可溶性LIFR拮抗LIF并减少VSMC钙化;LIF诱导VSMC中TYK2和STAT3磷酸化。
- TYK2抑制剂deucravacitinib减弱LIF效应并干扰磷酸盐促钙化;TYK2过表达加重VSMC钙化。
- 小鼠主动脉环钙化经Tyk2药理学抑制和遗传缺陷改善;胆钙化醇诱导的小鼠血管钙化经Tyk2抑制和Tyk2缺陷改善。
- Abcc6/Tyk2缺陷小鼠在腺嘌呤/高磷诱导CKD后钙化减轻。
临床怎么用
- TYK2信号可能作为减轻CKD血管钙化负担的潜在治疗靶点,deucravacitinib等TYK2抑制剂值得进一步临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Medial vascular calcification in chronic kidney disease (CKD) involves pro-inflammatory pathways induced by hyperphosphatemia. Several interleukin 6 family members have been associated with pro-calcific effects in vascular smooth muscle cells (VSMCs) and are considered as therapeutic targets. Therefore, we investigated the role of leukemia inhibitory factor (LIF) during VSMC calcification. LIF expression was found to be increased following phosphate exposure of VSMCs. LIF supplementation aggravated, while silencing of endogenous LIF or LIF receptor (LIFR) ameliorated the pro-calcific effects of phosphate in VSMCs. The soluble LIFR mediated antagonistic effects towards LIF and reduced VSMC calcification. Mechanistically, LIF induced phosphorylation of the non-receptor tyrosine-protein kinase 2 (TYK2) and signal transducer and activator of transcription-3 (STAT3) in VSMCs. TYK2 inhibition by deucravacitinib, a selective, allosteric oral immunosuppressant used in psoriasis treatment, not only blunted the effects of LIF, but also interfered with the pro-calcific effects induced by phosphate. Conversely, TYK2 overexpression aggravated VSMC calcification. Ex vivo calcification of mouse aortic rings was ameliorated by Tyk2 pharmacological inhibition and genetic deficiency. Cholecalciferol-induced vascular calcification in mice was improved by Tyk2 inhibition and in the Tyk2-deficient mice. Similarly, calcification was ameliorated in Abcc6/Tyk2-deficient mice after adenine/high phosphorus-induced CKD. Thus, our observations indicate a role for LIF in CKD-associated vascular calcification. Hence, the effects of LIF identify a central pro-calcific role of TYK2 signaling, which may be a future target to reduce the burden of vascular calcification in CKD.
引用
- Alesutan I, Razazian M, Luong TTD, et al. Augmentative effects of leukemia inhibitory factor reveal a critical role for TYK2 signaling in vascular calcification. Kidney Int. 2024. PMID: 39084258. doi:10.1016/j.kint.2024.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。